• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

RHB-104 - Articles and news items

Myelin deterioration multiple sclerosis

Last patient visit in Phase IIa study with RHB-104 for multiple sclerosis

Industry news / 3 August 2016 / RedHill Biopharma Ltd.

The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)…

RedHill Biopharma has last patient visit in phase IIa study with RHB-104 for multiple sclerosis

RedHill Biopharma has positive results with RHB-104 for multiple sclerosis

Industry news / 1 August 2016 / RedHill Biopharma Ltd.

RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period …

RHB-104

Encouraging top-line interim results for RHB-104 in RRMS

Industry news / 5 April 2016 / Victoria White

RedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +